AUS
NZ
UK
CA
USA
IND
_06_19_2026_12_34_15_139937.jpg)
Highlights
- Cardiol Therapeutics Inc. conducted a Phase II study for CardiolRx™ in recurrent pericarditis patients.
- Clinical results demonstrated sustained improvements in pain and inflammation over a 26-week period.
- The company announced plans for a Phase III trial to further evaluate the treatment.
The healthcare sector focuses on advancing treatments and solutions for complex medical conditions. Cardiol Therapeutics Inc. (TSX:CRDL), a clinical-stage biopharmaceutical company, works to develop anti-inflammatory and anti-fibrotic therapies targeting cardiovascular diseases. This effort includes the development of CardiolRx™, a cannabidiol-based therapy under investigation for recurrent pericarditis, a condition characterized by inflammation of the pericardial sac.
Phase II Study Results
The company conducted a Phase II study, known as the MAvERIC-Pilot trial, to evaluate the effects of CardiolRx™ on symptomatic recurrent pericarditis patients. The study extended over 26 weeks, with the findings presented at the American Heart Association Scientific Sessions 2024. Results revealed that improvements in pain and inflammation observed during the primary endpoint were sustained throughout the extension period.
The presentation highlighted data shared as part of the Laennec Clinician-Educator Award & Lecture. Dr. S. Allen Luis, a prominent figure in cardiovascular medicine at the Mayo Clinic, shared the results on behalf of the investigative team.
Planned Phase III Trial
Building on the promising outcomes of the Phase II study, Cardiol Therapeutics announced the initiation of a Phase III trial, MAVERIC-3. This trial will evaluate the long-term efficacy of CardiolRx™ in preventing recurrence of pericarditis. Designed with rigorous methodologies, the Phase III trial aims to address the unmet needs of patients experiencing recurrent episodes of this condition.
Parallel Research Efforts
Cardiol Therapeutics is advancing its research portfolio with another Phase II/III trial, MAVERIC-2. This study explores the effectiveness of CardiolRx™ in patients following the cessation of interleukin-1 blocker therapy. Both trials signify the company's commitment to providing solutions for pericarditis management through innovative research.
